Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Developmen... (uce fast effective and convenienttreatme...)

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects

Date:2/26/2009

uce fast, effective and convenient treatment for breakthrough cancer pain. Results from Phase III trails show NasalFent to have class-leading characteristics. This product, which has blockbuster potential, is targeted for launch in 2010 and Archimedes will market it through its own sales teams in Western Europe. Archimedes' other pipeline products include intranasal Apomorphine for advanced Parkinson's disease and intranasal Diazepam for acute repetitive seizures.

Archimedes technologies - ChiSys(R), PecSys and TARGIT(R) - are also used in a number of partnered products in late-stage clinical development. Additionally, Archimedes' innovative drug delivery technology has proven potential for vaccine delivery with pre-clinical and clinical studies of nasally administered vaccines demonstrating enhanced immune response.

Archimedes marketed products include Gliadel, a biodegradable wafer impregnated with an anti-cancer drug, carmustine, for high-grade glioma; Zomorph and Oramorph both morphine products for pain; and Pabrinex, a high potency vitamin formulation used to treat the symptoms of malnutrition especially in patients with acute alcohol problems.

Archimedes Pharma is UK based, with offices in Reading and development facilities in Nottingham. Further European commercial operations are established in Ireland, France and Germany. The Company was founded in December 2004 and is backed by Warburg Pincus, a leading private equity investor with extensive experience in the healthcare sector. In 2008, Archimedes had sales of GBP20.4 million.

Enquiries

Archimedes Pharma: Michael Clark, +44-118-931-5050

Citigate Dewe Rogerson: Chris Gardner/Heather Keohane, +44-207-638-9571 (media enquiries)

Trout International LLC: Mike Booth, +44-20-7936-9326 (investor enquiries)

For more information on Archimedes, visit:

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer

Post Your Comments:

(Date:11/5/2009)...ll/ -- Air Methods Corporation (Nasdaq: AIRM ) re... 2009. Revenue increased 3% to $137.6 million fro... nine-month period, revenue increased 3% to $390.4... nine-month period. The prior-year quarter and ni...enerated from hurricane response activities, as co...

(Date:11/5/2009)...re-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) ...ird quarter and nine months ended September 30, 20... quarter of 2009 of $8.8 million, or $0.19 per sha...$0.36 per share, in the third quarter of 2008. ,...d President of InterMune, said, "The third quarter...

(Date:11/5/2009)... 5 PDI, Inc. (Nasdaq: PD...upport to U.S. pharmaceutical companies, today rep...ird quarter ended September 30, 2009. ,, Comme... Executive Officer of PDI, Inc., stated, "Third qu...an last year by approximately 14%. Higher revenue...

Breaking Medicine Technology:Air Methods Reports 3Q2009 Results and 4Q2009 Update 2 Air Methods Reports 3Q2009 Results and 4Q2009 Update 3 Air Methods Reports 3Q2009 Results and 4Q2009 Update 4 Air Methods Reports 3Q2009 Results and 4Q2009 Update 5 Air Methods Reports 3Q2009 Results and 4Q2009 Update 6 Air Methods Reports 3Q2009 Results and 4Q2009 Update 7 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 2 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 3 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 4 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 5 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 6 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 7 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 8 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 9 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 10 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 11 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 12 InterMune Reports Third Quarter 2009 Financial Results and Business Highlights 13 PDI Reports 2009 Third Quarter Financial Results 2 PDI Reports 2009 Third Quarter Financial Results 3 PDI Reports 2009 Third Quarter Financial Results 4 PDI Reports 2009 Third Quarter Financial Results 5 PDI Reports 2009 Third Quarter Financial Results 6 PDI Reports 2009 Third Quarter Financial Results 7 PDI Reports 2009 Third Quarter Financial Results 8 PDI Reports 2009 Third Quarter Financial Results 9 PDI Reports 2009 Third Quarter Financial Results 10 PDI Reports 2009 Third Quarter Financial Results 11 General Practitioners Write Most Prescriptions for Mental Health Drugs According to Study from Thomson Reuters and SAMHSA 5081 1 General Practitioners Write Most Prescriptions for Mental Health Drugs According to Study from Thomson Reuters and SAMHSA 5081 2 Clearly Contacts Director of Web Sales Named as One of Canada 26apos 3Bs Top Online Marketers of 2009 58502 1 Clearly Contacts Director of Web Sales Named as One of Canada 26apos 3Bs Top Online Marketers of 2009 58502 2 Online Healthcare Community TogetherMD is Live 58498 1 Online Healthcare Community TogetherMD is Live 58498 2

[0] Air Methods Reports 3Q2009 Results and 4Q2009 Update [0] InterMune Reports Third Quarter 2009 Financial Results and Business Highlights [0] PDI Reports 2009 Third Quarter Financial Results

...ma partners with Diakron, MORRIS PLAINS, N.J., Au...y the signing of an exclusive license agreement fo...candidate discovered and,developed through Phase I...ms of the agreement, Diakron has the exclusive rig...bute the compound worldwide., In a simultaneous t...

...Calif., Aug. 12 DURECT Corporation,(Nasdaq: DRRX...istration,(FDA) has accepted the New Drug Applicat.... The FDA typically grants Priority Review to drug... significant improvements,compared to marketed pro...g,with Priority Review status is six months from t...

Other Medicine Technology:Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc. 2 REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 2 REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted 3

Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted

(Date:11/5/2009)...ICSBURG, Pa., Nov. 5 Sel... SEM ), the parent of Select Medical Corporation,...ed September 30, 2009. ,, For the third quarter...increased 5.1% to $545.6 million compared to $519....e from operations decreased 9.0% to $32.9 million ...

(Date:11/5/2009)...BURG, Ill., Nov. 5 Sinc...itive for the 2009 H1N1 influenza virus, pet owner...learn more: Can my pet get sick? What would the sy...ow is it treated? ,, The American Veterinary Me...act with experts and agencies across the country t...

(Date:11/5/2009)...esearchers have received two NIH grants of $1 mill...ntrolled personal health records to improve health...ents. , Both studies are funded through the fede...estment Act. , One study will look at using mob...onal health record to help HIV patients, adherence...

(Date:11/5/2009)... Lumenis® Ltd. a global developer...and radiofrequency devices for ophthalmic, surgica...initiation of a clinical study into the efficacy o...ar Edema (DME). The study will take place at the T...ship of Prof. Anat Loewenstein MD. , ...

(Date:11/5/2009)... Emdat, a world leader in online-base... its new CEO, effective immediately. , ... a world leader in online-based medical transcript...ive immediately., , , , ,Emdat’s founding p...ess, selected Olver to serve as CEO of the 10-year...

[1] Select Medical Holdings Corporation Announces Results for Third Quarter Ended September 30, 2009 [1] AVMA Updates H1N1 Flu Resources for Pet Owners, Veterinarians [0] Federal stimulus funds support studies geared to improving HIV care and prevention [1] Lumenis Announces the Initiation of a Clinical Study into the Efficacy of Selective Retina Therapy (SRT) in Diabetic Macular Edema (DME)[1] Randy Olver Named Emdat CEO, Will Lead Next Phase of Growth for Medical Transcription Solutions Provider

... and Drug Administration has approved the first ho...old by Organon, Inc., effectively blocks conceptio... meaning that for every 100 women who use it for a...tch, which releases a steady stream of estrogen an...

...s an abnormal dilation of a blood vessel. This inv...e a risk to health due to their potential to ruptu...essels involved are the abdominal and thoracic aor...// Some people are born with a malformation of a b...

... of C-reactive protein, induced by periodontal dis... according to US researchers. Previous research...infections could cause the liver to release increa...n established. A research team led by Dr Barb...

...tery disease is underdiagnosed and treated in many...se (PAD), the arteries in the legs and arms become...aque - which cause coronary artery disease. The be...alk with ease. Positive effects are seen within th...

...e, the bacterium blamed for the Black Death during...cal weapon, has had its entire genome sequenced. T...arranging themselves and picking up new genes from...atively easy to develop as weapons. The bacil...

...confirms that the main ingredient in the -- depo m...gnificant bone loss when used long term. The young..., the greater your risk of bone-related problems l...-balanced design that keeps bone density -- the th...

Other Medicine News:Health News:Sequencing of the Plague 2

FDA Approves Contraceptive Ring Detecting brain aneurysms Heart disease correlation to periodontal disease Wake-up call for peripheral artery disease Sequencing of the Plague Hormone contraceptives lead to bone problems

Maverick Over-The-Wire 25 mm Catheter

Maverick Over-The-Wire 15 mm Catheter

...ated Phoroptor features lighted dials to make it e... the darkened setting of the exam room. Put away y...the entire process. The Illuminated Phoroptor feat...xis scales that are easier than ever to see. The I...

Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder Black

Medicine Products:

Maverick Over-The-Wire 25 mm Catheter Maverick Over-The-Wire 15 mm Catheter Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder White Illuminated PHOROPTOR Refracting Instrument - Plus Cylinder Black

Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Developmen...(uce fast effective and convenienttreatme...),Health